• Include these codes as defined in http://smart.who.int/immunizations/CodeSystem/IMMZ.D version 📦0.2.0

  Code	Display	Definition
  DE263	Birth dose	Indicates if the client received a dose within 24 hours of birth. Whether a birth dose is counted as part of the primary series will depend on the antigen
  DE203	Completed the primary vaccination series	Indicates if the client has completed the primary vaccination series of a product/antigen. If the client has not yet completed their primary series, it means they may be expected to receive more doses to complete their vaccination regimen for the respective product/antigen
  DE257	Completed the booster series	Indicates if the client has completed the booster series of a product/antigen
  DE242	Date when primary vaccination series was completed	The date when the client completed the primary vaccination series (per product/antigen)
  DE204	HIV status	The current HIV status of the client
  DE208	Preterm birth	The infant was preterm; the mother gave birth to the infant when gestational age was less than 37 weeks
  DE209	Immunocompromised	The client is known to be immunocompromised. This means the client has a weakened immune system and having a reduced ability to fight infections and other diseases
  DE210	Currently on ART	The client is currently receiving antiretroviral therapy (ART)
  DE243	Type of TB infection test performed	The type of tuberculosis (TB) infection test performed
  DE246	TB infection test result	Records the result of the TB infection test
  DE249	Immunologically stable	The client is living with HIV and is immunologically stable with CD4 count or percentage above a minimum as defined in the HIV guidelines
  DE250	Clinically well	The client is living with HIV and is clinically well, as defined in HIV guidelines and WHO clinical staging
  DE211	Birth weight in grams	Represents the client's birth weight value measures in grams
  DE215	ART start date	The date on which the client started or restarted ART
  DE251	High risk of pneumococcal infection	The client is at high risk for pneumococcal infection because of underlying medical conditions (i.e. HIV infection or sickle-cell disease)
  DE236	Age in months when client received first meningococcal dose	The age in months when client received their first meningococcal dose
  DE240	VNA level	Vaccine-induced neutralizing antibody (VNA) level, measured as a serum antibody concentration from the result of the concentrated, purified cell culture-derived and embryonated egg-based rabies vaccines (CCEEV)
  DE253	Risk of occupational exposure to rabies virus	Professional at risk of occupational exposure to rabies virus, particularly animal health workers. Also considered for medical professionals who regularly provide care to persons with rabies
  DE241	Dengue serostatus	Indicates the result of a serological test determining whether the client has antibodies against the dengue virus
  DE201	Contact date	The date and time of the client's contact
  DE202	ANC contact number	The antenatal care (ANC) contact or visit number

This value set expansion contains 21 concepts.